Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Jazz Pharmaceuticals PLC Call to Discuss Exclusive License Agreement with Pharma Mar SA for Lurbinectedin in the U.S. Transcript

Jan 10, 2020 / 01:30PM GMT
Release Date Price: $146.68 (+0.75%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Jazz Pharmaceuticals Investor Update Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Kathee Littrell, Head of Investor Relations. Ma'am, you may begin.

Katherine A. Littrell
Jazz Pharmaceuticals plc - VP of IR

Thank you, Crystal, and thanks to those of you joining our investor update call today to discuss our exclusive license agreement with PharmaMar for lurbinectedin in the U.S. The press release and the slide presentation accompanying this call are available on the Investors section of our website.

I'd like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts and are forward-looking. Examples include statements regarding the potential benefits of the license agreement for lurbinectedin, including the potential accelerated FDA approval and the launch of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot